Abstract
Ovarian and other hormones are major determinants of breast cancer risk. Particularly important is the accumulative exposure of the breast to circulating levels of the ovarian hormones estradiol and progesterone. A number of breast cancer risk factors can be understood in light of how they affect women's hormone profiles. Age is a marker for the onset and cessation of ovarian activity. Racial differences in hormone profiles correlate with breast cancer incidence patterns. Age at menarche not only serves as the chronological indicator of the onset of ovarian activity, but as a predictor of ovulatory frequency during adolescence and hormone levels in young adults, and has a long-lasting influence on risk. Age at menopause, another established breast cancer risk factor, marks the cessation of ovarian activity. Pregnancy history and lactation experience also are hormonal markers of breast cancer risk. Postmenopausal obesity, which is associated with higher levels of estrogen following cessation of ovarian activity, increases breast cancer risk, whereas physical activity, which can limit menstrual function, reduces risk. A relatively recent area of investigation is prenatal exposures like preeclampsia and low birth weight; both may be associated with lower in utero exposure to estrogen and also may predict lower breast cancer risk as an adult. Improved understanding of these exposures and their potential interactions with breast cancer susceptibility genes may, in the future, improve our prospects for breast cancer prevention.
Similar content being viewed by others
REFERENCES
D.M. Parkin, S.L. Whelan, J. Ferlay, L. Raymond, and J. E. Young (eds.) (1997). Cancer Incidence in Five Continents, Vol.7, IARCScientific Publications No. 143, International Agency forResearch on Cancer, Lyon, France.
C.C. Boring, T.S. Squires, and T. Tong (1993). Cancer Statistics 1993. CA: Cancer J.Clin. 43: 7–26.
B.E. Henderson and H.S. Feigelson (2000). Hormonal carcino-genesis. Carcinogenesis 21: 427–433.
J. Waterhouse, C. Muir, K. Shanmugaratnam, and J.E. Powell(1982). Cancer Incidence in Five Continents, Vol. 4, IARC ScientificPublications No. 42, International Agency for Researchon Cancer, Lyon, France.
D.M. Parkin, C.S. Muir, S.L. Whelan, Y.T. Gao, J. Ferlay,and J. Powell (eds.) (1992). Cancer Incidence in Five Continents, IARCScientific Publications No. 120, International Agency forResearch on Cancer, Lyon, France.
B.A. Miller, L.N. Kolonel, L. Bernstein, J.L. Young Jr, G.M. Swanson, D. West, C.R. Key, J.M. Liff, C.S. Glover, and G.A. Alexander (eds.) (1996). Racial/Ethnic Patterns of Cancerin the United States 1988–1992I, NIH Pub. No. 96–4104, NationalCancer Institute, Bethesda, MD.
L. A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey,B.A. Miller, L. Clegg, and B.K. Edwards (eds.) (2001). SEERCancer Statistics Review, 1973–1998, National Cancer Institute,Bethesda, MD.
S. Preston-Martin, M.C. Pike, R.K. Ross, P.A. Jones, and B.E. Henderson (1990). Increased cell division as a cause of humancancer. Cancer Res. 50: 7415–7421.
I.A. Mustafa and K.I. Bland (1998). Physiologic effects ofsteroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Ann.Surg. 228: 638–651.
B.E. Henderson, R.K. Ross, H.L. Judd, M.D. Krailo, and M.C. Pike (1985). Do regular ovulatory cycles increase breastcancer risk? Cancer 56: 1206–1208.
U. Goebelsmann and D. Mishell (1979). The menstrual cycle. In D. Mishell and V. Davajan (eds.), Reproductive Endocrinology,Infertility and Contraception, FA Davis, Philadelphia, PA, pp. 67–89.
M.C. Pike, D.V. Spicer, L. Dahmoush, and M.F. Press (1993). Estrogens, progestogens, normal breast cell proliferation, andbreast cancer risk. Epidemiol.Rev. 15: 17–35.
L. Bernstein and R.K. Ross (1993). Hormones and breast cancer. Epidemiol.Rev. 15: 48–65.
T. Key (1999). Serum estradiol and breast cancer risk. Endocrine-Rel.Cancer 6: 175–180.
H.V. Thomas, G.K. Reeves, and T.J. Key (1997). Endogenousestrogen and postmenopausal breast cancer: Aquantitative review. Cancer Causes Control 8: 922–928.
S.E. Hankinson, W.C. Willett, J.E. Manson, G.A. Colditz, D.A. Hunter, D. Spiegelman, R.L. Barbieri, and F.E. Speizer(1998). Plasma sex steroid hormone levels and risk of breastcancer in postmenopausal women. J.Natl.Cancer Inst. 90: 1292–1299.
T. Zeginiadou, A.H. Kortsaris, S. Koliais, and O. Antonoglou(1998). Sex hormone binding globulin inhibits strongly the up-takeof estradiol by human breast carcinoma cells via a depri-vativemechanism. Cancer Biochem.Biophys. 16: 253–263.
J.F. Dorgan, C. Longcope, H.E. Stephenson, R.T. Falk,R. Miller, C. Franz, L. Kahle, W.S. Campbell, J.A. Tantrea, and A. Schatzkin (1996). Relation of prediagnostic serum estrogenand androgen levels to breast cancer risk. Cancer EpidemiolBiomark.Prev. 5: 533–539.
D.C. Anderson (1974). Sex-hormone-binding globulin. Clin.Endocrinol. 3: 69–96.
L.E. Nachtigall, U. Raju, S. Banerjee, L. Wan, and M. Levitz(2000). Serum estradiol-binding profiles in postmenopausalwomen undergoing three common estrogen replacement ther-apies:Associations with sex hormone-binding globulin, estra-diol,and estrone levels. Menopause 7: 243–250.
E.S. Knochenhauer, L.R. Boots, H.D. Potter, and R. Azziz(1998). Differential binding of estradiol and testosterone toSHBG. Relation to circulating estradiol levels. J.Reprod.Med. 43:665–670.
J.M. Cline, G. Soderqvist, E. von Schoultz, L. Skoog, and B. von Schoultz (1996). Effects of hormone replacement therapy onthe mammary gland of surgically postmenopausal macaques. Am.J.Obstet.Gynecol. 174: 93–100.
C. Schairer, C. Byrne, P.M. Keyl, L.A. Brinton, S.R. Sturgeon, and R.N. Hoover (1994). Menopausal estrogen and estrogen–progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5: 491–500.
R.K. Ross, A. Paganini-Hill, P.C. Wan, and M.C. Pike (2000). Effect of hormone replacement therapy on breast cancer risk:Estrogen versus estrogen plus progestin. J.Natl.Cancer Ins. 92: 328–332.
J.M. Grodin, P.K. Siiteri, and P.C. MacDonald (1973). Sourceof estrogen prouction in postmenopausal women. J.Clin.En-docrinol.Metab. 36: 207–214.
M.Lippman, G. Bolan, and K. Huff (1976). The effects of andro-gensand antiandrogens on hormone-responsive human breastcancer in long-term tissue culture. Cancer Res. 36: 4610–4618.
P. Hill, L. Garbaczewski, and F. Kasumi (1985). Plasma testos-teroneand breast cancer. Eur.J.Clin.Oncol. 21: 1265–1266.
B.R. Goldin, H. Adlercreutz, S.L. Gorbach, M.N. Woods, J.T. Dwyer, T. Conlon, E. Bohn, and S.N. Gershoff (1986). Therelationship between estrogen levels and diets of CaucasianAmerican and Oriental immigrant women. Am.J.Clin.Nutr. 44: 945–953.
T. J.A. Key, J. Chen, D.Y. Wang, M.C. Pike, and J. Boreham(1990). Sex hormones in women in rural China and in Britain. Br.J.Cancer 62: 631–636.
H. Shimizu, R.K. Ross, L. Bernstein, M.C. Pike, and B.E. Henderson (1990). Serum estrogen levels in postmenopausalwomen: Comparison of US whites and Japanese in Japan. Br.J.Cancer 62: 451-4.
D.K. Wysowski, G.W. Comstock, K.J. Helsing, and H. L. Lau (1987). Sex hormone levels in serum in relation to thedevelopment of breast cancer. Am.J.Epidemiol. 125: 791–799.
K.J. Helzlsouer, A.J. Alberg, T.L. Bush, C. Longcope, G.B. Gordon, and G.W. Comstock (1994). A prospective study of endogenous hormones and breast cancer. Cancer Detect.Prev. 18: 79–85.
P. Ebeling and V.A. Koivisto (1994). Physiological importanceof dehydroepiandrosterone. Lancet 343: 1479–1481.
A.G. Schwartz (1979). Inhibition of spontaneous breast cancerformation in female C3H (Avy/a) mice by long-term treatmentwith dehydroepiandrosterone. Cancer Res. 39: 1129–1132.
J. H.H. Thijssen, J. Poortman, and F. Schwarz (1975). Andro-gensin postmenopausal breast cancer: Excretion, productionand interaction with estrogens. J.Steroid Biochem. 6: 729–734.
B.K. Vonderhaar (1987). Prolactin transport, function, and re-ceptorsin mammary gland development and differentiation.In M. Neville and C. Daniels (eds.), The Mammary GlandDevelopment, Regulation and Function, Plenum, New York, pp. 383–438.
B.K. Vonderhaar (1999). Prolactin involvement in breastcancer. Endocrine-Rel.Cancer 6: 389–404.
C.W. Welsch and H. Nagasawa (1977). Prolactin and murinemammary tumorigenesis: A review. Cancer Res. 37: 951–963.
S.E. Hankinson, W.C. Willett, D.S. Michaud, J.E. Manson, G.A. Colditz, C. Longcope, B. Rosner, and F.E. Speizer (1999). Plasma prolactin levels and subsequent risk of breast cancer inpostmenopausal women. J.Natl.Cancer Inst. 91: 629–634.
B.E. Henderson, M.C. Pike, L. Bernstein, and R.K. Ross(1996). Breast cancer. In D. Schottenfeld and J. Fraumeni Jr. (eds.), Cancer Epidemiology and Prevention, 2nd edn., W.B. Saunders, New York, pp. 1022–1039.
B.E. Henderson, M.C. Pike, and J.T. Casagrande (1981). Breastcancer and the oestrogen window hypothesis. Lancet 2: 363–364.
D. Apter and R. Vihko (1983). Early menarche, a risk factor forbreast cancer, indicates early onset of ovulatory cycles. J.Clin.Endocrinol.Metab. 57: 82–86.
R. Vihko and D.J. Apter (1984). Endocrine characteristics ofadolescent menstrual cycles: Impact of early menarche. SteroidBiochem. 20: 231–236.
D. Apter, M. Reinila, and R. Vihko (1989). Some endocrinecharacteristics of early menarche, a risk factor for breast cancerare preserved into adulthood. In t.J.Cancer 44: 783–787.
D. Trichopoulos, B. MacMahon, and P. Cole (1972). Themenopause and breast cancer risk. J.Natl.Cancer Inst. 48: 605–613.
L.A. Brinton, C. Schairer, R.N. Hoover, and J.F. Fraumeni(1988). Menstrual factors and risk of breast cancer. Cancer Investig. 6: 245–254.
B. MacMahon, P. Cole, M.T. Lin, C.R. Lowe, A.P. Mirra,B. Ravnihar, E.J. Salber, V.G. Valaoras, and S. Yuasa (1970). Age at first birth and cancer of the breast. A summary of aninternational study. Bull.W.H.O. 43: 209–221.
J.M. Yuan, M.C. Yu, R.K. Ross, Y.T. Gao, and B.E. Henderson(1988). Risk factors for breast cancer in Chinese women inShanghai. Cancer Res. 48: 1949–1953.
P. Bruzzi, E. Negri, C. La Vecchia, A. Decarli, D. Palli, F. Parazzini, and M.R. Del Turco (1988). Short term increasein risk of breast cancer after full term pregnancy. Br.Med.J. 297: 1096–1098.
L. Bernstein, R.H. Depue, R.K. Ross, H.L. Judd, M.C. Pike,and B.E. Henderson (1986). Higher maternal levels of freeestradiol in first compared to second pregnancy: A study ofearly gestational differences. J.Natl.Cancer Inst. 75: 1035–1039.
S.M. Enger, R.K. Ross, H. B. E, and L. Bernstein (1997). Breastfeeding history, pregnancy experience and risk of breast cancer. Br.J.Cancer 76: 118–123.
R.H. Depue, L. Bernstein, R.K. Ross, H.L. Judd, M.C. Pike,and B.E. Henderson (1987). Hyperemesis gravidarum in rela-tionto estradiol levels, pregnancy outcome, and other maternal. factors: A sero-epidemiologic study. Am.J.Obstet.Gynecol. 156: 1137–1141.
L. Bernstein, M.C. Pike, R.K. Ross, H.L. Judd, J.B. Brown, and B.E. Henderson (1985). Estrogen and sex hormone-bindingglobulin levels in nulliparous and parous women. J.Natl.CancerInst. 74: 741–745.
V.C. Musey, D.C. Collins, P.I. Musey, D. Martino-Saltzman,and J.R. Preedy (1987). Long-term effect of a first preg-nancyon the secretion of prolactin. New Engl.J.Med. 316: 229–234.
D.Y. Wang, B. L. de Stavola, R.D. Bulbrook, D.S. Allen, H.G. Kwa, A.A. Verstraeten, J.W. Moore, I.S. Fentiman, J.L. Hayward, and I.H. Gravelle (1988). The permanent effect ofreproductive events on blood prolactin levels and its relationto breast cancer risk: A population study of postmenopausalwomen. Eur.J.Cancer Clin.Oncol. 24: 1225–1231.
J.W. Moore, T. J.A. Key, R.D. Bulbrook, G.M. Clark,D.S. Allen, D.Y. Wang, and M.C. Pike (1987). Sex hormonebinding globulin and risk factors for breast cancer in a popu-lationof normal women who had never used exogenous sexhormones. Br.J.Cancer 56: 661–666.
P.A. Wingo, K. Newsome, J.S. Marks, E.E. Calle, and S.L. Parker (1997). The risk of breast cancer following sponta-neousand induced abortion. Cancer Causes Control 8: 93–108.
P.A. Newcomb, B.E. Storer, M.P. Longnecker, R. Mittendorf,E.R. Greenberg, R.W. Clapp, K.P. Burke, W.C. Willett, and B. MacMahon (1994). Lactation and a reduced risk of pre-menopausalbreast cancer. New Engl.J.Med. 330: 81–86.
S.M. Enger, R.K. Ross, A. Paganini-Hill, and L. Bernstein(1998). Breastfeeding experience and breast cancer risk amongpostmenopausal women. Cancer Epidemiol.Biomark.Prev. 7: 365–369.
D.J. Hunter and W.C. Willett (1993). Diet, body size, and breastcancer. Epidemiol.Rev. 15: 110–132.
Z. Huang, S.E. Hankinson, G.A. Colditz, M.J. Stampfer,D.J. Hunter, J.E. Manson, C.H. Hennekens, B. Rosner,F.E. Speizer, and W.C. Willett (1997). Dual effects of weightand weight gain on breast cancer risk. J.Am.Med.Assoc. 278: 1407–1411.
P.K. Siiteri and P.C. MacDonald (1973). Role of extraglan-dularestrogen in human endocrinology. In S.R. Geiger, E.B. Astwood, and R.O. Greep (eds.), Handbook of Physiology, American Physiological Society, Washington, DC, pp. 615–629.
T. J.A. Key and M.C. Pike (1988a). The dose–effect relationship between “unopposed” oestrogens and endometrial mitoticrate: Its central role in explaining and predicting endometrial cancer risk. Br.J.Cancer 57: 205–212.
G. Ursin, M.P. Longnecker, R.W. Haile, and S. Greenland(1995). A meta-analysis of body mass index and risk of pre-menopausalbreast cancer. Epidemiology 6: 137–141.
M.C. Pike (1990). Reducing cancer risk in women throughlifestyle-mediated changes in hormone levels. Cancer Detect.Prev. 14: 595–607.
L. Bernstein and B.E. Henderson (1996). Exogenous hormones. In D. Schottenfeld and J. Fraumeni Jr. (eds.), Cancer Epidemiology and Prevention, 2nd edn., W.B. Saunders, New York, pp. 462–488.
L. Bernstein, M.C. Pike, M. Krailo, and B.E. Henderson (1990). Update of the Los Angeles study of oral contraceptives andbreast cancer: 1981 and 1983. In R. Mann (ed.), Oral Contra-ceptivesand Breast Cancer, Parthenon, Park Ridge, NJ, pp. 169–180.
G. Ursin, R.K. Ross, J. Sullivan-Halley, R. Hanisch, B.E. Henderson, and L. Bernstein (1998). Use of oral contracep-tivesand risk of breast cancer in young women. Breast CancerRes.Treat. 50: 175–184.
Collaborative Group on Hormonal Factors in Breast Cancer. (1996a). Breast cancer and hormonal contraceptives. Lancet 347: 1713–1727.
Collaborative Group on Hormonal Factors in Breast Cancer. (1996b). Breast cancer and hormonal contraceptives: Furtherresults. Contraception S 54: 1–106.
J.L. Stanford and D.B. Thomas (1993). Exogenous progestinsand breast cancer. Epidemiol.Rev. 15: 98–107.
M.C. Pike, L. Bernstein, and D.V. Spicer (1993). The re-lationshipof exogenous hormones to breast cancer risk. In J. Niederhuber (ed.), Current Therapy in Oncology, Mosby, St. Louis, MO, pp. 292–303.
T.J. Key and M.C. Pike (1988b). The role of oestrogens and pro-gestagensin the epidemiology and prevention of breast cancer. Eur.J.Cancer Clin.Oncol. 13: 29–43.
C. Magnusson, J.A. Baron, N. Correia, R. Bergstrom,H.O. Adami, and I. Persson (1999). Breast-cancer risk follow-inglong-term oestrogen-and oestrogen-progestin-replacementtherapy. In t.J.Cancer 81: 339–344.
C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover (2000). Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. J.Am.Med.Assoc. 283: 485–491.
R.E. Frisch, A.V. Gotz-Welbergen, J.W. McArthur,T. Albright, J. Witschi, B. Bullen, J. Birnholz, and R.B. Reed(1981). Delayed menarche and amenorrhea of college athletesin relation to age of onset of training. J.Am.Med.Assoc. 246: 1559–1563.
B. Schwartz, D.C. Cumming, E. Riordan, M. Selye, S.S. Yen,and R.W. Rebar (1981). Exercise-associated amenorrhea: Adistinct entity? Am.J.Obstet.Gynecol. 141: 662–670.
M.M. Shangold and H.A. Levine (1982). The effect ofmarathon training upon menstrual function. Am.J.Obstet.Gynecol. 143: 862–869.
M.M. Shangold (1985). Exercise and amenorrhea. Sem.Re-prod Endocrinol. 3: 35–43.
E. Dale, D. Gerlach, and A.L. Wilhite (1979). Menstrual dys-functionin distance runners. Obstet.Gynecol. 54: 47–53.
K.M. Pirke, U. Schweiger, A. Broocks, R.J. Tuschl, and R.G. Laessle (1990). Luteinizing hormone and follicle stim-ulatinghormone secretion patterns in female athletes withand without menstrual disturbances. Clin.Endocrinol. 33: 345–353.
A. Broocks, K.M. Pirke, U. Schweiger, R.J. Tuschl,R.G. Laessle, T. Strowitzki, E. Horl, T. Horl, W. Haas, and D. Jeschke (1990). Cyclic ovarian function in recreational ath-letes. J.Appl.Physiol. 68: 2083–2086.
J.C. Prior, Y.M. Vigna, M.T. Schechter, and A.E. Burgess(1990). Spinal bone loss and ovulatory disturbances. New Engl.J.Med. 323: 1221–1227.
L. Bernstein, R.K. Ross, R.A. Lobo, R. Hanisch, M.D. Krailo,and B.E. Henderson (1987). The effects of moderate physicalactivity on menstrual cycle patterns in adolescence: Implica-tionsfor breast cancer prevention. Br.J.Cancer 55: 681–685.
J.B. Russell, D. Mitchell, P.I. Musey, and D.C. Collins (1984). The relationship of exercise to anovulatory cycles in female ath-letes:Hormonal and physical characteristics. Obstet.Gynecol. 63: 452–456.
C.M. Friedenreich and T.E. Rohan (1995). Areview of physicalactivity and breast cancer. Epidemiology 6: 311–317.
A. McTiernan, C. Ulrich, S. Slate, and J. Potter (1998). Physi-calactivity and cancer etiology: Associations and mechanisms. Cancer Causes Control 9: 487–509.
L. Bernstein, B.E. Henderson, R. Hanisch, J. Sullivan-Halley,and R.K. Ross (1994). Physical exercise and reduced risk ofbreast cancer in young women. J.Natl.Cancer Inst. 86: 1403–1408.
C.L. Carpenter, R.K. Ross, A. Paganini-Hill, and L. Bernstein(1999). Lifetime exercise activity and breast cancer risk amongpost-menopausal women. Br.J.Cancer 80: 1852–1858.
G. Jasienska, I. Thune, and P.T. Ellison (2000). Energeticfactors, ovarian steroids and the risk of breast cancer. Eur.J.Cancer Prev. 9: 231–239.
J. Russo and I.H. Russo (1987). Development of the human mammary gland. In M. Neville and C. Daniel (eds.), The Mam-maryGland, Plenum, New York, pp. 67–93.
D. Trichopoulos (1990). Hypothesis: Does breast cancer origi-natein utero? Lancet 335: 939–940.
R. Anbazhagan and B.A. Gusterson (1994). Prenatal factorsmay influence predisposition to breast cancer. Eur.J.Cancer A 30: 1–3.
E. Petridou, K. Panagiotopoulou, K. Katsouyanni, E. Spanos,and D. Trichopoulos (1990). Tobacco smoking, pregnancy estrogens,and birth weight. Epidemiology 1: 247–250.
A. Ekbom, D. Trichopoulos, H.O. Adami, C.C. Hsieh, and S.J. Lan (1992). Evidence of prenatal influences on breastcancer risk. Lancet 340: 1015–1018.
K.B. Michels, D. Trichopoulos, J.B. Robins, B.A. Rosner,J.E. Manson, D.J. Hunter, G.A. Colditz, S.E. Hankinson,F.E. Speizer, and W.C. Willett (1996). Birthweight as a riskfactor for breast cancer. Lancet 348: 1542–1546.
A. Ekbom, C.C. Hsieh, L. Lipworth, H.O. Adami, and D. Trichopoulos (1997). Intrauterine environment and breastcancer risk in women: Apopulation-based study. J.Natl.CancerInst. 89: 71–76.
A. Shibata and A.Y. Minn (2000). Perinatal sex hormones and risk of breast and prostate cancers in adulthood. Epidemiol.Rev. 22: 239–248.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernstein, L. Epidemiology of Endocrine-Related Risk Factors for Breast Cancer. J Mammary Gland Biol Neoplasia 7, 3–15 (2002). https://doi.org/10.1023/A:1015714305420
Issue Date:
DOI: https://doi.org/10.1023/A:1015714305420